Supplemental Figure S6 from KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine
Year: 2023
Type: supplementary-materials
Abstract: A, tumor mass of the excised tumor at four weeks of treatment and change in tumor volume as measured by caliper for each tumor normalized to day zero of low dose decitabine (20 mg/kg, SC, 3x per week) or vehicle administered for four weeks in a subcutaneous xenograft model using a KRAS-mutant cell line (OVCAR8) (*, p = 0.03; Mann-Whitney). B, tumor mass of the excised tumor at four weeks of treatment and change in tumor volume for each tumor normalized to day zero of low-dose decitabine (20 mg/kg SC, 3x per week), navitoclax (100 mg/kg IP, 5x per week), or vehicle treatment administered alone or in combination for four weeks in a subcutaneous xenograft model using a KRAS-mutant cell line (OVCAR8) (**, p < 0.001; t-test). Week four treatment omitted one injection of decitabine and two injections of navitoclax.
Authors: Michelle L. Stewart, Pablo Tamayo, Andrew J. Wilson, Stephanie Wang, Yun Min Chang, Jong W. Kim, Dineo Khabele, Alykhan F. Shamji, Stuart L. Schreiber
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362289266